128 filings
Page 5 of 7
6-K
hbb fa6z3kmwde5cesi
23 Apr 20
ObsEva Announces Publication of Abstracts from Phase 2b EDELWEISS Trial of Linzagolix in Endometriosis
4:00pm
6-K
crr lja85vg91b
14 Apr 20
ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares
6:41am
6-K
6sl r5pygi
7 Apr 20
Current report (foreign)
5:30pm
6-K
swai l6l359hzf6ba
6 Apr 20
ObsEva SA Announces New Interim Chief Financial Officer
4:00pm
6-K
dfn8w
27 Mar 20
Current report (foreign)
7:19am
6-K
rab2 yiui4mgk
23 Mar 20
ObsEva Provides Update Related to COVID-19 Pandemic
4:00pm
6-K
zxxp mmac9js
5 Mar 20
Current report (foreign)
4:10pm
6-K
db6 fea3t93
15 Jan 20
Current report (foreign)
8:35pm
6-K
5gwj4 z3aw3h08h
10 Dec 19
ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix
12:00am
6-K
0hbj6wr bxvlh
13 Nov 19
Index to Unaudited Condensed Consolidated Financial Statements
4:00pm
6-K
40wx4flevf1kxdq9jdm
7 Nov 19
Current report (foreign)
9:11am
6-K
9g3ydumhhnn5wh2k2
31 Oct 19
ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical
4:21pm
6-K
3nxd4prf8jy7
12 Sep 19
ObsEva announces new composition of its Executive Committee
8:16am
6-K
3v9fbz
6 Sep 19
ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of
8:27am
6-K/A
wj2gpj24u6d 4am5yfc3
9 Aug 19
Current report (foreign) (amended)
3:22pm
6-K
k2muu1dvw
7 Aug 19
ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC
4:18pm
6-K
i3ywn7rvqmr
7 Aug 19
Current report (foreign)
7:21am
6-K
d21gqvgs4n ord
7 Aug 19
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
l522idqljvt eq2
18 Jul 19
Current report (foreign)
4:05pm
6-K
ug3xy
5 Jul 19
Current report (foreign)
6:01pm